These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24369034)

  • 21. [Schizophrenia: receptors and clinical aspects].
    Azorin JM
    Encephale; 1997 Apr; 23 Spec No 2():17-9. PubMed ID: 9273301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspects of oxidative metabolism in schizophrenia.
    Marchbanks RM; Mulcrone J; Whatley SA
    Br J Psychiatry; 1995 Sep; 167(3):293-8. PubMed ID: 7496636
    [No Abstract]   [Full Text] [Related]  

  • 24. [Receptor antagonist of NMDA and animal models of schizophrenia].
    Bian SZ; Zhang J; Liu WL; Sun ZH; Gu ZL; Jiang XG
    Fa Yi Xue Za Zhi; 2009 Dec; 25(6):443-6. PubMed ID: 20225623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 27. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
    Schmidt-Hansen M; Le Pelley M
    Cogn Neuropsychiatry; 2012 Nov; 17(6):473-505. PubMed ID: 22443090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The schizophrenic mind.
    Begley S
    Newsweek; 2002 Mar; 139(10):44-51. PubMed ID: 11894588
    [No Abstract]   [Full Text] [Related]  

  • 30. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
    Tarazi FI; Riva MA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurotrophins and schizophrenia.
    Buckley PF; Mahadik S; Pillai A; Terry A
    Schizophr Res; 2007 Aug; 94(1-3):1-11. PubMed ID: 17524622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder.
    Gogos JA
    Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurochemical circuitry of schizophrenia.
    Carlsson A
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S10-4. PubMed ID: 16508890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Of rats and schizophrenia.
    Boksa P
    J Psychiatry Neurosci; 2007 Jan; 32(1):8-10. PubMed ID: 17245468
    [No Abstract]   [Full Text] [Related]  

  • 35. [Neurodevelopmental theories of schizophrenia--preclinical studies].
    Lehner M; Taracha E; Wisłowska A; Zienowicz M; Maciejak P; Skórzewska A; Płaźnik A
    Psychiatr Pol; 2003; 37(4):627-39. PubMed ID: 14560492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schizophrenia: treatment targets beyond monoamine systems.
    Ibrahim HM; Tamminga CA
    Annu Rev Pharmacol Toxicol; 2011; 51():189-209. PubMed ID: 20868275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive impairment in schizophrenia and how it affects treatment options.
    Bilder RM
    Can J Psychiatry; 1997 Apr; 42(3):255-64. PubMed ID: 9114941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bridging pharmacology and neurodevelopment in schizophrenia.
    Kato T
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):713-6. PubMed ID: 17651523
    [No Abstract]   [Full Text] [Related]  

  • 39. Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam.
    Du Y; Grace AA
    Int J Neuropsychopharmacol; 2016 Nov; 19(11):. PubMed ID: 27432008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neurobiology and treatment of mentalisation in schizophrenia].
    Herold R; Tényi T
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):187-93. PubMed ID: 16496483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.